MedTrace Logo

Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab

NCT07363642 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-04-22

No results posted yet for this study

Summary

This study aims to explore the potential for Tezepelumab-treated severe asthmatic patients to effectively and safely reduce their background maintenance medication while maintaining asthma symptom control.

Conditions

Interventions

DRUG

Tezepelumab

Severe asthma taking medium-high dose ICS/LABA with up to one additional controller will be enrolled into this single arm treatment

Sponsors & Collaborators

Principal Investigators

  • KeFang Lai, Professor · The First Affiliated Hospital of Guangzhou Medical University

  • FengMing Luo, Professor · Sichuan University West China Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-28
Primary Completion
2027-08-07
Completion
2029-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07363642 on ClinicalTrials.gov